Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated
Advocates scandalized that Gilead's hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billions in profits.